Chemist + Druggist is part of Informa PLC


This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

PSNC will ask for five-year contract with earlier monthly payments

PSNC will be asking for a multi-year funding settlement, with earlier monthly payments and reimbursement for FMD costs, in its upcoming negotiations.

In negotiations it hopes to start in April, the Pharmaceutical Services Negotiating Committee (PSNC) said it will be looking for a settlement of “more than one year, hopefully up to five” akin to the new GP contract announced last month.

PSNC will call for a longer contract to allow contractors “some time to understand the future and to plan and deal with your businesses accordingly”, director of funding Mike Dent said in a video shown to delegates at the Sigma conference in Muscat, Oman on Sunday (February 17).

“There is a lag to get the full money”

The negotiator will also be addressing the timing of contractors’ monthly payments, Mr Dent said.

“One of the most complex things [contractors] deal with is the whole advance recovery process. You're never quite sure how much you're going to get paid, so we'd like to be able to clarify that for you.”

This could be possible if the proportion of items dispensed via the electronic prescription service (EPS) increases to between 80% and 90% following the service’s full rollout, he added.

PSNC’s regional representative for north-west England Fin McCaul said that as more prescriptions become electronic, “there's no reason why we couldn't get paid as close as possible to when we need to pay for our wholesaler bills that month”.

At the moment, “there is a lag for us to get the full money” from the NHS Business Services Authority of up to two months after dispensing, Mr McCaul told C+D.

“If we get paid for everything that was dispensed in January at the end of February, then when we pay our wholesaler bills it's really manageable.”

Full reimbursement for FMD

Mr Dent said PSNC will also ask the Department of Health and Social Care (DH) for “recognition of the costs of implementing the Falsified Medicines Directive (FMD)”.

The EU’s anti-counterfeit legislation – which requires all pharmacies to be able to scan barcodes on medicines packaging at the point of dispensing – came into force on February 9.

Building on a commitment announced in October to discuss FMD remuneration with the DH, Mr McCaul said PSNC would look for funding to cover the costs of hardware, software and staff workload.

The cost of hardware and software is “very little compared to the processing costs” of staff scanning packaging, Mr McCaul said.

“We will be looking at all scenarios for that and negotiating with the DH as to what's the most appropriate funding mechanism.”

Any funding for FMD compliance will be discussed in negotiations post-April, Mr McCaul said.

“The DH are not going to pay us upfront for it anyway, because they'll always retrospectively pay,” he added.

Follow @CandDThomas on Twitter to catch up with all the latest coverage from the Sigma conference in Muscat.

What do you think PSNC's priorities for the next round of negotiations should be?

Related Content

Topics



Pharmacist Managers - Recruiting Now !
East London, Essex and Luton
£40,000 - £50,000 per year

Apply Now
UsernamePublicRestriction

Register

CD005761

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel